Royal Bank Of Canada Zynerba Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.33 - $1.39 $4,057 - $17,090	-12,295 Reduced 97.5%	315 $0
Q2 2023 Aug 14, 2023	BUY	$0.3 - $0.43 $533 - $764	1,779 Added 16.43%	12,610 $4,000
Q1 2023 May 15, 2023	BUY	$0.4 - $0.67 $4,252 - $7,122	10,631 Added 5315.5%	10,831 $4,000
Q4 2022 Feb 14, 2023	SELL	$0.5 - $0.72 $1,034 - $1,488	-2,068 Reduced 91.18%	200 $0
Q3 2022 Nov 14, 2022	BUY	$0.87 - $1.36 $1,973 - $3,084	2,268 New	2,268 $2,000
Q2 2022 Aug 15, 2022	SELL	$0.86 - $2.06 $3,375 - $8,085	-3,925 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.83 - $3.02 $7,182 - $11,853	3,925 New	3,925 $8,000
Q4 2021 Feb 14, 2022	SELL	$2.88 - $4.3 $6,249 - $9,331	-2,170 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.72 - $5.35 $12,473 - $17,938	-3,353 Reduced 60.71%	2,170 $9,000
Q2 2021 Aug 16, 2021	BUY	$3.83 - $5.98 $21,153 - $33,027	5,523 New	5,523 $29,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.